Prognostic and predictive value of IDO expression in metastatic melanoma treated with Ipilimumab
The exact role of IDO in creating an immunosuppressive tumor environment and its reversal needs to be further elucidated.
Authors
- Christian Hafner (ORCID: https://orcid.org/0000-0002-6444-6840)
- Simone M. Goldinger (ORCID: https://orcid.org/0000-0002-7995-7301)
- Waltraud Fröhlich
- Katharina C. Kähler (ORCID: https://orcid.org/0000-0001-9953-0893)
- Dirk Schadendorf (ORCID: https://orcid.org/0000-0003-3524-7858)
- Michael Constantin Kirchberger (ORCID: https://orcid.org/0000-0002-9573-3009)
- Carola Berking (ORCID: https://orcid.org/0000-0003-0229-8931)
- Stefan Schliep
- Nora Kramer (ORCID: https://orcid.org/0009-0003-1496-8207)
- Dagmar von Bubnoff
- Reinhard Dummer (ORCID: https://orcid.org/0000-0002-2279-6906)
- Christina Schmitt (ORCID: https://orcid.org/0000-0001-9592-2347)
- Lucie Heinzerling
Institutions
- Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
- LMU Klinikum (DE)
- University Hospital Regensburg (DE)
- Universitätsklinikum Erlangen (DE)
- University Hospital of Zurich (CH)
- University Hospital Schleswig-Holstein (DE)
- Essen University Hospital (DE)
- Comprehensive Cancer Center Erlangen (DE)
- Ludwig-Maximilians-Universität München (DE)
- University of Lübeck (DE)
Publication Details
- Journal
- PLoS ONE
- Published
- 2025-05-07
- DOI
- https://doi.org/10.1371/journal.pone.0321937
- Citations
- 3
- Primary Topic
- Tryptophan and brain disorders
- Type
- article
- Field-Weighted Citation Impact
- 1.73
Funders
- Amgen
- Bristol-Myers Squibb
- Pfizer
- Sanofi
- Array BioPharma
- Regeneron Pharmaceuticals
- Les Laboratories Pierre Fabre
- Sun Pharma
- Medac
- Genentech